4SC AG Ár/értékesítés
Mi az 4SC AG Ár/értékesítés?
A Ár/értékesítés az 4SC AG - 54.57
Mi a Ár/értékesítés meghatározása?
Az ár / árbevétel arány a vállalat részvényeinek árbevételéhez képest.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Ár/értékesítés a Health Care szektor a XETRA-on cégekben a 4SC AG -hoz képest
Mit csinál 4SC AG?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
ár/értékesítés -hoz hasonló cégek 4SC AG
- Eagle Capital Growth Fund nak Ár/értékesítés 54.33 van
- Bluefield Solar Income Fund nak Ár/értékesítés 54.35 van
- Gensight Biologics SA nak Ár/értékesítés 54.37 van
- Agios Pharmaceuticals Inc nak Ár/értékesítés 54.44 van
- Invitrocue nak Ár/értékesítés 54.46 van
- Sanwaria Consumer nak Ár/értékesítés 54.50 van
- 4SC AG nak Ár/értékesítés 54.57 van
- Soligenix Inc nak Ár/értékesítés 54.61 van
- The State Trading of India nak Ár/értékesítés 54.68 van
- Ascentage Pharma Grp Intl nak Ár/értékesítés 54.83 van
- Envision Solar International nak Ár/értékesítés 54.91 van
- Envision Solar International nak Ár/értékesítés 54.91 van
- SPDR Dow Jones Industrial Average ETF Trust nak Ár/értékesítés 54.93 van